Cargando…
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine
BACKGROUND: Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grow...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080346/ https://www.ncbi.nlm.nih.gov/pubmed/21477311 http://dx.doi.org/10.1186/1471-2407-11-124 |
_version_ | 1782202103701176320 |
---|---|
author | Verreault, Maite Strutt, Dita Masin, Dana Anantha, Malathi Yung, Andrew Kozlowski, Piotr Waterhouse, Dawn Bally, Marcel B Yapp, Donald T |
author_facet | Verreault, Maite Strutt, Dita Masin, Dana Anantha, Malathi Yung, Andrew Kozlowski, Piotr Waterhouse, Dawn Bally, Marcel B Yapp, Donald T |
author_sort | Verreault, Maite |
collection | PubMed |
description | BACKGROUND: Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. METHODS: Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx(®); 15 mg/kg) and irinotecan (Irinophore C™; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K(trans)). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. RESULTS: The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p < 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p < 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p < 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K(trans )in the orthotopic tumors (p < 0.05). CONCLUSION: The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature. |
format | Text |
id | pubmed-3080346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30803462011-04-21 Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine Verreault, Maite Strutt, Dita Masin, Dana Anantha, Malathi Yung, Andrew Kozlowski, Piotr Waterhouse, Dawn Bally, Marcel B Yapp, Donald T BMC Cancer Research Article BACKGROUND: Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. METHODS: Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx(®); 15 mg/kg) and irinotecan (Irinophore C™; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K(trans)). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. RESULTS: The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p < 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p < 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p < 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K(trans )in the orthotopic tumors (p < 0.05). CONCLUSION: The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature. BioMed Central 2011-04-08 /pmc/articles/PMC3080346/ /pubmed/21477311 http://dx.doi.org/10.1186/1471-2407-11-124 Text en Copyright ©2011 Verreault et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Verreault, Maite Strutt, Dita Masin, Dana Anantha, Malathi Yung, Andrew Kozlowski, Piotr Waterhouse, Dawn Bally, Marcel B Yapp, Donald T Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine |
title | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine |
title_full | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine |
title_fullStr | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine |
title_full_unstemmed | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine |
title_short | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine |
title_sort | vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (irinophore c™), doxorubicin (caelyx(®)) or vincristine |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080346/ https://www.ncbi.nlm.nih.gov/pubmed/21477311 http://dx.doi.org/10.1186/1471-2407-11-124 |
work_keys_str_mv | AT verreaultmaite vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT struttdita vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT masindana vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT ananthamalathi vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT yungandrew vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT kozlowskipiotr vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT waterhousedawn vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT ballymarcelb vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine AT yappdonaldt vascularnormalizationinorthotopicglioblastomafollowingintravenoustreatmentwithlipidbasednanoparticulateformulationsofirinotecanirinophorecdoxorubicincaelyxorvincristine |